 | | Vol. 11.00 – 17 January, 2025 |
| |
|
|
| Scientists evaluated the efficacy and safety of the radiation–immune checkpoint inhibitor combination in patients with locally advanced rectal cancer in a Phase II, randomized trial conducted in eight major colorectal cancer centers in Beijing.
[Nature Medicine] |
|
|
|
 | | PUBLICATIONSListed by the impact factor of the journal |
|
|
|
| Investigators conducted a randomized Phase II trial to evaluate efficacy and safety of dual-HER2 inhibition against standard-of-care anti-EGFR antibody–based therapy as second/third-line treatment in HER2-positive metastatic colorectal cancer.
[Journal of Clinical Oncology] |
|
|
|
| Scientists investigated intrinsic resistance mechanisms to KRAS inhibitors using patient-derived colorectal cancer cells (CRC-PDCs). They found that KRAS-mutated CRC-PDCs could be divided into at least an EGFR pathway-activated group and a PI3K/AKT pathway-activated group.
[NPJ Precision Oncology] |
|
|
|
| Researchers showed that inhibiting oxidative phosphorylation similarly suppressed the proliferation and tumorigenicity of glycolytically competent colorectal cancer (CRC) cells in vitro and in patient-derived CRC xenografts.
[Cell Death & Disease] |
|
|
|
| Forkhead Box D1 (FOXD1) knock down in the non-β1,4-N-acetylgalactosaminyltransferase 2 (B4GALNT2) expresser cell line SW948 stimulated B4GALNT2. Thus, FOXD1 and miR-204-5p emerged as crucial new player of B4GALNT2 down-regulation in colorectal cancer.
[Scientific Reports] |
|
|
|
| Researchers suggested that G-protein gamma subunit 2 (GNG2) contributed to tumor suppression in colorectal cancer (CRC), particularly in preventing brain metastasis, and could serve as a promising biomarker and treatment target for metastatic CRC.
[Scientific Reports] |
|
|
|
| Investigators assessed MIR210 host gene (MIR210HG) expression in colon cancer cell lines and tissues, and examined the effects of its overexpression and knockdown on cell proliferation.
[Scientific Reports] |
|
|
|
|
| The authors underscore the need for continued research on polysaccharide-based colon-targeted drug delivery systems for colon cancer treatment, offering a path toward more effective, patient-centered oncological care.
[International Journal of Biological Macromolecules] |
|
|
|
|
| China’s NMPA has approved Astellas Pharma’s VYLOYTM, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.
[Astellas Pharma] |
|
|
|
|
| | Punta Cana, Dominican Republic |
|
|
|
|
|
| | Technical University of Munich – Munich, Germany |
|
|
|
| | University of California San Francisco – San Francisco, California, United States |
|
|
|
| | The University of Arizona – Tucson, Arizona, United States |
|
|
|
| | University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
| | Columbia University – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
